mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2025-6-25-34mrj-1875Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL GUIDELINESКомментарии к рекомендациям EULAR по применению противоревматических препаратов в репродуктивном периоде, во время беременности и лактацииComments on the EULAR recommendations on the use of antirheumatic drugs in reproduction, pregnancy, and lactationhttps://orcid.org/0000-0003-3236-4485ТрофимовЕ. А.TrofimovE. A.

191015, Санкт-Петербург, ул. Кирочная, 41

41, Kirochnaya Street, Saint Petersburg 191015

https://orcid.org/0000-0002-0797-2051МазуровВ. И.MazurovV. I.

191015, Санкт-Петербург, ул. Кирочная, 41

41, Kirochnaya Street, Saint Petersburg 191015

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А; 125993, Москва, ул. Баррикадная, 2/1, стр. 1

34A, Kashirskoe Shosse, Moscow 115522; 2/1, Barrikadnaya Street, Build. 1, Moscow 125993

https://orcid.org/0000-0002-1098-1418ГриваА. И.GrivaA. I.

Арина Игоревна Грива

191015, Санкт-Петербург, ул. Кирочная, 41

Arina Igorevna Griva

41, Kirochnaya Street, Saint Petersburg 191015

griva.arina@yandex.ruhttps://orcid.org/0000-0002-1317-8276СвинцицкаяИ. С.SvintsitskayaI. S.

194044, Санкт-Петербург, ул. Академика Лебедева, 6Ж

6Zh, Akademika Lebedeva Street, Saint Petersburg 194044

https://orcid.org/0000-0001-7651-7709ЛиходкинВ. А.LikhodkinV. A.

194044, Санкт-Петербург, ул. Академика Лебедева, 6Ж

6Zh, Akademika Lebedeva Street, Saint Petersburg 194044

https://orcid.org/0000-0001-5926-7912ТрофимоваА. С.TrofimovaA. S.

191015, Санкт-Петербург, ул. Кирочная, 41

41, Kirochnaya Street, Saint Petersburg 191015

ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава РоссииРоссияNorth-Western State Medical University named after I.I. Mechnikov, Ministry of Health of RussiaRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian FederationФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова», Минобороны РоссииРоссияS.M. Kirov Military Medical Academy, Ministry of Defense of RussiaRussian Federation2025221220251962534Copyright © Трофимов Е.А., Мазуров В.И., Лила А.М., Грива А.И., Свинцицкая И.С., Лиходкин В.А., Трофимова А.С., 20252025Трофимов Е.А., Мазуров В.И., Лила А.М., Грива А.И., Свинцицкая И.С., Лиходкин В.А., Трофимова А.С.Trofimov E.A., Mazurov V.I., Lila A.M., Griva A.I., Svintsitskaya I.S., Likhodkin V.A., Trofimova A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1875

С момента публикации в 2016 г. положений EULAR о применении противоревматических препаратов до зачатия, во время беременности и кормления грудью появились результаты ряда исследований о безопасности указанных препаратов в эти периоды, что позволило существенно обновить предыдущую версию. Новые данные дают возможность повысить уровень доказательности для некоторых препаратов. Все рекомендации поддерживаются экспертным консенсусом с высоким уровнем согласия. В обновленную версию включены рекомендации по применению противоревматических препаратов у женщин и мужчин, планирующих зачатие, а также во время беременности и лактации.

Since the publication in 2016 of the EULAR statements on the use of antirheumatic drugs before conception, during pregnancy, and breastfeeding, results of several studies on the safety of these drugs in these periods have appeared, allowing a substantial update of the previous version. New data make it possible to increase the level of evidence for some medications. All recommendations are supported by expert consensus with a high degree of agreement. The updated version includes recommendations on the use of antirheumatic drugs in women and men planning conception, as well as during pregnancy and lactation.

рекомендации EULARревматические заболеванияпротиворевматические препаратырепродуктивное здоровьебеременностьпериод лактацииEULAR recommendationsrheumatic diseasesantirheumatic drugsreproductive healthpregnancylactation periodИсследование не имело спонсорской поддержкиThe investigation has not been sponsoredReferencesGötestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016 May;75(5):795810. doi: 10.1136/annrheumdis-2015-208840.Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016 May;75(5):795810. doi: 10.1136/annrheumdis-2015-208840.Rüegg L, Pluma A, Hamroun S, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025 Jun;84(6):910-926. doi: 10.1016/j.ard.2025.02.023.Rüegg L, Pluma A, Hamroun S, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025 Jun;84(6):910-926. doi: 10.1016/j.ard.2025.02.023.Pluma A, Hamroun S, Rüegg L, et al. Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations. Ann Rheum Dis. 2025 Sep;84(9):1561-1590. doi: 10.1016/j.ard.2025.02.021.Pluma A, Hamroun S, Rüegg L, et al. Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations. Ann Rheum Dis. 2025 Sep;84(9):1561-1590. doi: 10.1016/j.ard.2025.02.021.Singh M, Wambua S, Lee SI, et al; MuM-PreDiCT. Autoimmune diseases and adverse pregnancy outcomes: an umbrella review. BMC Med. 2024 Mar 5;22(1):94. doi: 10.1186/s12916-024-03309-y.Singh M, Wambua S, Lee SI, et al; MuM-PreDiCT. Autoimmune diseases and adverse pregnancy outcomes: an umbrella review. BMC Med. 2024 Mar 5;22(1):94. doi: 10.1186/s12916-024-03309-y.Bosshard N, Zbinden A, Eriksson KK, Förger F. Rituximab and Canakinumab Use During Lactation: No Detectable Serum Levels in Breastfed Infants. Rheumatol Ther. 2021 Jun;8(2):1043-1048. doi: 10.1007/s40744-021-00313-z. Epub 2021 May 17.Bosshard N, Zbinden A, Eriksson KK, Förger F. Rituximab and Canakinumab Use During Lactation: No Detectable Serum Levels in Breastfed Infants. Rheumatol Ther. 2021 Jun;8(2):1043-1048. doi: 10.1007/s40744-021-00313-z. Epub 2021 May 17.Russell MD, Dey M, Flint J, et al; BSR Standards, Audit and Guidelines Working Group. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory antirheumatic drugs and corticosteroids. Rheumatology (Oxford). 2023 Apr 3;62(4):e48-e88. doi: 10.1093/rheumatology/keac551.Russell MD, Dey M, Flint J, et al; BSR Standards, Audit and Guidelines Working Group. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory antirheumatic drugs and corticosteroids. Rheumatology (Oxford). 2023 Apr 3;62(4):e48-e88. doi: 10.1093/rheumatology/keac551.Chambers CD, Johnson DL, Xu R, et al; OTIS Collaborative Research Group. Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort Study. Arthritis Rheumatol. 2022 Apr;74(4):711-724. doi: 10.1002/art.42015.Chambers CD, Johnson DL, Xu R, et al; OTIS Collaborative Research Group. Birth Outcomes in Women Who Have Taken Hydroxycholoroquine During Pregnancy: A Prospective Cohort Study. Arthritis Rheumatol. 2022 Apr;74(4):711-724. doi: 10.1002/art.42015.Nørgеrd BM, Friedman S, Kjeldsen J, Nielsen J. The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study. Aliment Pharmacol Ther. 2022 Nov; 56(9):1349-1360. doi: 10.1111/apt.17189.Nørgеrd BM, Friedman S, Kjeldsen J, Nielsen J. The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study. Aliment Pharmacol Ther. 2022 Nov; 56(9):1349-1360. doi: 10.1111/apt.17189.Torres J, Chaparro M, Julsgaard M, et al. European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. J Crohns Colitis. 2023 Jan 27;17(1):1-27. doi: 10.1093/ecco-jcc/jjac115.Torres J, Chaparro M, Julsgaard M, et al. European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. J Crohns Colitis. 2023 Jan 27;17(1):1-27. doi: 10.1093/ecco-jcc/jjac115.Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020 Apr;72(4):529-556. doi: 10.1002/art.41191.Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2020 Apr;72(4):529-556. doi: 10.1002/art.41191.Dathe K, Frank J, Padberg S, et al. Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort. BMC Pregnancy Childbirth. 2022 Aug 26;22(1): 666. doi: 10.1186/s12884-022-04986-4.Dathe K, Frank J, Padberg S, et al. Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort. BMC Pregnancy Childbirth. 2022 Aug 26;22(1): 666. doi: 10.1186/s12884-022-04986-4.Choi EY, Jeong HE, Noh Y, et al. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: A nationwide cohort study. PLoS Med. 2023 Feb 27;20(2):e1004183. doi: 10.1371/journal.pmed.1004183.Choi EY, Jeong HE, Noh Y, et al. Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: A nationwide cohort study. PLoS Med. 2023 Feb 27;20(2):e1004183. doi: 10.1371/journal.pmed.1004183.Трофимов ЕА, Мазуров ВИ, Гайдукова ИЗ. Применение ингибиторов фактора некроза опухоли у пациенток с ревматоидным артритом во время беременности: собственные наблюдения. Терапия. 2019; (8):59-66.Trofimov EA, Mazurov VI, Gaidukova IZ. The use of tumor necrosis factor inhibitors in patients with rheumatoid arthritis during pregnancy: own observations. Terapiya. 2019;(8):59-66. (In Russ.).Orozco-Guillen AO, Abraham VS, Moguel Gonzalez B, et al. Kidney-Limited Full-House Lupus-like Membranous Nephropathy and Membranoproliferative Glomerulonephritis in Pregnancy. Kidney Int Rep. 2023 Jan 16;8(4):932-938. doi: 10.1016/j.ekir.2023.01.006.Orozco-Guillen AO, Abraham VS, Moguel Gonzalez B, et al. Kidney-Limited Full-House Lupus-like Membranous Nephropathy and Membranoproliferative Glomerulonephritis in Pregnancy. Kidney Int Rep. 2023 Jan 16;8(4):932-938. doi: 10.1016/j.ekir.2023.01.006.Rüegg L, Hamroun S, Sanjurjo A, et al. POS0886 No increased risks of serious infections in infants after in-utero exposure to tnf inhibitors: a systematic review and metaanalysis informing the EULAR task force on antirheumatic drugs in reproduction, pregnancy and lactation. Ann Rheum Dis. 2024; 83:1144-1145. doi: 10.1136/annrheumdis2024-eular.2677.Rüegg L, Hamroun S, Sanjurjo A, et al. POS0886 No increased risks of serious infections in infants after in-utero exposure to tnf inhibitors: a systematic review and metaanalysis informing the EULAR task force on antirheumatic drugs in reproduction, pregnancy and lactation. Ann Rheum Dis. 2024; 83:1144-1145. doi: 10.1136/annrheumdis2024-eular.2677.Perez-Garcia LF, Dolhain RJEM, Vorstenbosch S, et al. The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review. Hum Reprod Update. 2020 Nov 1; 26(6):961-1001. doi: 10.1093/humupd/ dmaa022.Perez-Garcia LF, Dolhain RJEM, Vorstenbosch S, et al. The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review. Hum Reprod Update. 2020 Nov 1; 26(6):961-1001. doi: 10.1093/humupd/ dmaa022.Andersen JB, Wandall-Holm MF, Magyari M. Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population. Mult Scler Relat Disord. 2022 Mar;59:103529. doi: 10.1016/j.msard.2022.103529.Andersen JB, Wandall-Holm MF, Magyari M. Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population. Mult Scler Relat Disord. 2022 Mar;59:103529. doi: 10.1016/j.msard.2022.103529.Perez-Garcia LF, Röder E, Krijthe BP, et al. Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX). Ann Rheum Dis. 2023 Aug;82(8):1068-1075. doi: 10.1136/ard-2023-224032.Perez-Garcia LF, Röder E, Krijthe BP, et al. Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX). Ann Rheum Dis. 2023 Aug;82(8):1068-1075. doi: 10.1136/ard-2023-224032.

The authors declare that there are no conflicts of interest present.